# EDGAR Filing Document

**Accession Number:** 0000875657
**File Stem:** 0001437749-25-025482
**Filing Date:** 2025-8
**Character Count:** 24246
**Document Hash:** 45feda710e23e3e0bc39dad1f3549d5f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-025482.hdr.sgml**: 20250807

**ACCESSION NUMBER**: 0001437749-25-025482

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20250807

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250807

**DATE AS OF CHANGE**: 20250807

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ULTRALIFE CORP
- **CENTRAL INDEX KEY:** 0000875657
- **STANDARD INDUSTRIAL CLASSIFICATION:** MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 161387013
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-20852
- **FILM NUMBER:** 251195056

**BUSINESS ADDRESS:**
- **STREET 1:** 2000 TECHNOLOGY PARKWAY
- **CITY:** NEWARK
- **STATE:** NY
- **ZIP:** 14513
- **BUSINESS PHONE:** 3153327100

**MAIL ADDRESS:**
- **STREET 1:** 2000 TECHNOLOGY PARKWAY
- **CITY:** NEWARK
- **STATE:** NY
- **ZIP:** 14513

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ULTRALIFE BATTERIES INC
- **DATE OF NAME CHANGE:** 19940224

?xml version='1.0' encoding='ASCII'? ulbi20250806_8k.htm

---

| | | |
|:---|:---|:---|
| **UNITED STATES** | **UNITED STATES** | **UNITED STATES** |
| **SECURITIES AND EXCHANGE COMMISSION** | **SECURITIES AND EXCHANGE COMMISSION** | **SECURITIES AND EXCHANGE COMMISSION** |
| **Washington, D.C. 20549** | **Washington, D.C. 20549** | **Washington, D.C. 20549** |
| **FORM 8-K** | **FORM 8-K** | **FORM 8-K** |
| **CURRENT REPORT**<br> **Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** | **CURRENT REPORT**<br> **Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** | **CURRENT REPORT**<br> **Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** |
| **August 7, 2025** | **August 7, 2025** | **August 7, 2025** |
| Date of Report (Date of Earliest Event Reported) | Date of Report (Date of Earliest Event Reported) | Date of Report (Date of Earliest Event Reported) |
| **ULTRALIFE CORPORATION** | **ULTRALIFE CORPORATION** | **ULTRALIFE CORPORATION** |
| (Exact name of registrant as specified in its charter) | (Exact name of registrant as specified in its charter) | (Exact name of registrant as specified in its charter) |
| **Delaware** | **000-20852** | **16-1387013** |
| (State of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| **2000 Technology Parkway, Newark, New York 14513** | **2000 Technology Parkway, Newark, New York 14513** | **2000 Technology Parkway, Newark, New York 14513** |
| (Address of principal executive offices) (Zip Code) | (Address of principal executive offices) (Zip Code) | (Address of principal executive offices) (Zip Code) |
| **(315) 332-7100** | **(315) 332-7100** | **(315) 332-7100** |
| (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) |
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |

---

---

| | | |
|:---|:---|:---|
| **(Title of each class)** | **(Trading Symbol)** | **(Name of each exchange on which registered)** |
| Common Stock, $0.10 par value per share | ULBI | NASDAQ |

---

---

| |
|:---|
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |
| ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging Growth Company ☐<br>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |

---

------

**Item 2.02 Results of Operations and Financial Condition**

On August 7, 2025, Ultralife Corporation issued a press release regarding the financial results for its second quarter ended June 30, 2025. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.

**Item 9.01 Financial Statements, Pro Forma Financials and Exhibits**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Exhibit Description** |
| 99.1 | [Press Release of Ultralife Corporation dated August 7, 2025](ex_849403.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: August 7, 2025 |  | **ULTRALIFE CORPORATION** |
|  | By: | /s/ Philip A. Fain |
|  |  | Philip A. Fain |
|  |  | Chief Financial Officer and Treasurer |

---

## Exhibit 99.1

**Exhibit 99.1**

![ex_849403img001.jpg](ex_849403img001.jpg)

**Ultralife Corporation Reports Second Quarter Results**

NEWARK, N.Y. – August 7, 2025 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the second quarter ended June 30, 2025 with the following results:

● Sales of $48.6 million increased 13.0% from $43.0 million for the second quarter of 2024; excluding Electrochem, sales of $39.3 million declined 8.7% due to a 57.2% decrease in Communications Systems sales

● Gross profit of $11.6 million, or 23.9% of revenue, compared to $11.6 million, or 26.9% of revenue, for the second quarter of 2024

● Operating income of $2.3 million, including one-time non-recurring costs and purchase accounting adjustments of $0.3 million, compared to $3.9 million for the second quarter of 2024

● GAAP EPS of $0.05 compared to $0.18 for the second quarter of 2024

● Adjusted EBITDA of $4.1 million compared to $5.4 million for the second quarter of 2024

● Backlog with high confidence orders of $89 million compared to $95 million exiting the first quarter of 2025

"The second quarter was a challenging period for Ultralife. While the addition of Electrochem lifted revenue, Battery & Energy Products organic sales were essentially flat and Communications Systems sales declined due to delayed purchase orders. We also faced headwinds from tariffs, unfavorable product mix shifts across our business and order timing, which collectively impacted gross profit. Nevertheless, we continued to invest in new product development, with several offerings advancing into validation and production. We also applied the proceeds from our Employee Retention Credit collected during the quarter to prepay some of our acquisition debt, paying down a total of $2.7 million, $2.0 million more than our quarterly debt amortization requirement," said Mike Manna, President and Chief Executive Officer.

"Notwithstanding the challenges experienced in the second quarter, we expect improved results in the second half of the year and into 2026. We expect our Communications Systems business to rebound from a tough first half, and we are also beginning to see early purchase orders from long-term new product programs for our battery business, a rebound in demand from our medical and oil & gas customers, sustained growth in global defense spending, and an expanding opportunity pipeline across both businesses," added Manna. "Our priorities remain converting long-term new product development efforts into revenue, advancing vertical integration in the oil & gas segment, and maintaining a strong focus on operational efficiency initiatives to deliver sustainable profitable growth and maximizing the value of our global brand."

------

**<u>Second Quarter 2025 Financial Results</u>**

Revenue was $48.6 million, an increase of $5.6 million, or 13.0%, as compared to revenue of $43.0 million for the second quarter of 2024. Battery & Energy Products sales increased 25.0% to $45.9 million compared to $36.7 million last year reflecting the inclusion of Electrochem Solutions, Inc. ("Electrochem"). Excluding Electrochem, Battery & Energy Products sales were essentially flat year-over-year with government/defense sales increasing 61.1%, reflecting strong demand from a U.S.-based global prime, offset by a 20.4% decrease in commercial sales, primarily reflecting declines in medical and oil & gas sales. Communications Systems sales decreased by 57.2% to $2.7 million compared to $6.3 million for the same period last year, primarily attributable to shipments in the prior year of integrated systems to a major international defense contractor, magnified by delays in the timing of purchase orders during the current period. Our total backlog and high-confidence orders exiting the second quarter was $89 million compared to $95 million reported for the first quarter of 2025, reflecting the timing of order placement.

Gross profit was $11.6 million, or 23.9% of revenue, compared to $11.6 million, or 26.9% of revenue, for the same quarter a year ago. Battery & Energy Products gross margin was 23.6%, compared to 27.1% last year, primarily due to product mix, higher tariff and freight costs and lower factory throughput at some of our locations. Communications Systems gross margin was 28.4% compared to 25.6% last year, primarily due to product mix somewhat muted by lower volume.

Operating expenses were $9.3 million, compared to $7.6 million for the second quarter of 2024, reflecting the inclusion of Electrochem, a 25.3% increase in new product development costs related to continued investment in our product offering, and one-time, non-recurring expenses. Operating expenses were 19.2% of revenue compared to 17.8% of revenue for the year-earlier period.

Operating income was $2.3 million compared to $3.9 million last year. Driven by the 57.2% decline in Communications Systems sales, the decline in Battery & Energy Products gross margin and non-recurring costs, operating margin decreased to 4.6% compared to 9.1% last year.

Other expense, reported below operating income was $1.1 million, comprised of interest expense from the financing of the Electrochem acquisition and foreign currency loss from the weakening of the U.S. dollar, compared to $.1 million for the same period last year. The 2024 amount included a $0.2 million payment from our insurance carrier pertaining to the cyberattack which occurred in the first quarter of 2023.

Net income attributable to Ultralife Corporation was $.9 million or $0.05 per diluted share on a GAAP basis, compared to $3.0 million or $0.18 per diluted share for the second quarter of 2024. Adjusted EPS was $0.07 on a diluted basis for the second quarter of 2025, compared to $0.22 for the 2024 period. Adjusted EPS excludes the provision for deferred taxes which primarily represents non-cash charges for U.S. taxes which we expect will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future.

Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense, was $4.1 million for the second quarter of 2025, or 8.5% of sales, compared to $5.4 million, or 12.6% of sales, for the year-earlier period. On a trailing twelve-month basis, adjusted EBITDA was $15.4 million or 8.6% of sales.

See the "Non-GAAP Financial Measures" section of this release for a reconciliation of adjusted EPS to EPS and adjusted EBITDA to net income attributable to Ultralife Corporation.

------

**About Ultralife Corporation**

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government/defense and commercial customers across the globe.

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit <u>www.ultralifecorporation.com</u>.

**Conference Call Information**

-

Ultralife will hold its second quarter earnings conference call today at Noon ET.

To ensure a fast and reliable connection to our investor conference call, we now require participants dialing in by phone to register using the following link prior to the call: <u>https://register-conf.media-server.com/register/BIbda86e3ea7b342b6944287e49c2d3e9c</u>. This will eliminate the need to speak with an operator. Once registered, dial-in information will be provided along with a personal identification number. Should you register early and misplace your details, you can simply click back on this same link at any time to register and view this information again. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at <u>http://investor.ultralifecorporation.com</u>. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include uncertain global economic conditions including the impact of tariffs and inflation, reductions in revenues from key customers, delays or reductions in U.S. and foreign military spending, acceptance of our new products on a global basis, and disruptions, delays or material price increases in our supply of raw materials and components due to business conditions, new or additional tariffs, global conflicts, weather or other factors not under our control. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife's financial results is included in Ultralife's Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

------

**ULTRALIFE CORPORATION AND SUBSIDIARIES**

**CONSOLIDATED BALANCE SHEETS**

**(Dollars in Thousands)**

**(Unaudited)**

**ASSETS**

---

| | | |
|:---|:---|:---|
|  | **June 30,**  | **December 31,** |
|  | **2025** | **2024** |
| Current Assets: |  |  |
| Cash | $10941 | $6854 |
| Trade Accounts Receivable, Net | 32322 | 29370 |
| Inventories, Net | 50575 | 51363 |
| Prepaid Expenses and Other Current Assets | 5165 | 9573 |
| Total Current Assets | 99003 | 97160 |
| Property, Plant and Equipment, Net | 40614 | 40485 |
| Goodwill | 45406 | 45006 |
| Other Intangible Assets, Net | 23839 | 24557 |
| Deferred Income Taxes, Net | 7688 | 8413 |
| Other Non-Current Assets | 4411 | 4830 |
| Total Assets | $220961 | $220451 |
| **LIABILITIES AND SHAREHOLDERS' EQUITY** | **LIABILITIES AND SHAREHOLDERS' EQUITY** | **LIABILITIES AND SHAREHOLDERS' EQUITY** |
| Current Liabilities: |  |  |
| Accounts Payable | $15029 | $14160 |
| Current Portion of Long-Term Debt | 3438 | 2750 |
| Accrued Compensation and Related Benefits | 2674 | 2911 |
| Accrued Expenses and Other Current Liabilities | 8757 | 9470 |
| Total Current Liabilities | 29898 | 29291 |
| Long-Term Debt, Net | 47510 | 51502 |
| Deferred Income Taxes | 1400 | 1443 |
| Other Non-Current Liabilities | 3508 | 4028 |
| Total Liabilities | 82316 | 86264 |
| Shareholders' Equity: |  |  |
| Common Stock | 2108 | 2107 |
| Capital in Excess of Par Value | 192350 | 191828 |
| Accumulated Deficit | (31698) | (34442) |
| Accumulated Other Comprehensive Loss | (2820) | (4006) |
| Treasury Stock | (21492) | (21492) |
| Total Ultralife Equity | 138448 | 133995 |
| Non-Controlling Interest | 197 | 192 |
| Total Shareholders' Equity | 138645 | 134187 |
| Total Liabilities and Shareholders' Equity | $220961 | $220451 |

---

------

---

| |
|:---|
| **ULTRALIFE CORPORATION AND SUBSIDIARIES** |
| **CONSOLIDATED STATEMENTS OF INCOME**<br> **(In Thousands Except Per Share Amounts)** |
| **(Unaudited)** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three-Month Period Ended** | **Three-Month Period Ended** | **Six-Month Period Ended** | **Six-Month Period Ended** |
|  | **June 30,** | **June 30,** | **June 30,** | **June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| **Revenues:** |  |  |  |  |
| Battery & Energy Products | $45867 | $36683 | $92188 | $71672 |
| Communications Systems | 2694 | 6300 | 7119 | 13238 |
| **Total Revenues** | 48561 | 42983 | 99307 | 84910 |
| **Cost of Products Sold:** |  |  |  |  |
| Battery & Energy Products | 35032 | 26730 | 69913 | 52733 |
| Communications Systems | 1928 | 4690 | 5048 | 9144 |
| **Total Cost of Products Sold** | 36960 | 31420 | 74961 | 61877 |
| **Gross Profit** | 11601 | 11563 | 24346 | 23033 |
| **Operating Expenses:** |  |  |  |  |
| Research and Development | 2318 | 1997 | 4722 | 3753 |
| Selling, General and Administrative | 7027 | 5649 | 13969 | 11300 |
| Total Operating Expenses | 9345 | 7646 | 18691 | 15053 |
| **Operating Income** | 2256 | 3917 | 5655 | 7980 |
| **Other Expense** | 1143 | 71 | 2096 | 527 |
| **Income Before Income Taxes** | 1113 | 3846 | 3559 | 7453 |
| Income Tax Provision | 243 | 853 | 810 | 1556 |
| **Net Income** | 870 | 2993 | 2749 | 5897 |
| Net Income (Loss) Attributable to Non-Controlling Interest | (9) | 24 | 5 | 37 |
| **Net Income Attributable to Ultralife Corporation** | $879 | $2969 | $2744 | $5860 |
| **Net Income Per Share Attributable to Ultralife Common Shareholders** – **Basic** | $0.05 | $0.18 | $0.17 | $0.36 |
| **Net Income Per Share Attributable to Ultralife Common Shareholders** – **Diluted** | $0.05 | $0.18 | $0.17 | $0.35 |
| **Weighted Average Shares Outstanding** – **Basic** | 16635 | 16658 | 16634 | 16482 |
| **Weighted Average Shares Outstanding** – **Diluted** | 16656 | 16825 | 16671 | 16661 |

---

------

**Non-GAAP Financial Measures**

**Adjusted EBITDA**

In evaluating our business, we consider and use adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance in addition to GAAP financial measures. We define adjusted EBITDA as net income attributable to Ultralife Corporation before net interest expense, provision for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We reconcile adjusted EBITDA to net income attributable to Ultralife Corporation, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.

---

| |
|:---|
| **ULTRALIFE CORPORATION AND SUBSIDIARIES** |
| **CALCULATION OF ADJUSTED EBITDA** |
| **(Dollars in Thousands)** |
| **(Unaudited)** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three-Month Period Ended** | **Three-Month Period Ended** | **Six-Month Period Ended** | **Six-Month Period Ended** |
|  | **June 30,** <br> **2025** | **June 30,** <br> **2024** | **June 30,** <br> **2025** | **June 30,** <br> **2024** |
| Net Income Attributable to Ultralife Corporation | $879 | $2969 | $2744 | $5860 |
| Adjustments: |  |  |  |  |
| Interest Expense, Net | 992 | 418 | 2024 | 938 |
| Income Tax Provision | 243 | 853 | 810 | 1556 |
| Depreciation Expense | 1008 | 789 | 1958 | 1529 |
| Amortization Expense | 410 | 227 | 815 | 455 |
| Stock-Based Compensation Expense | 235 | 159 | 462 | 320 |
| Severance Cost for Plant Closure |  |  | 150 |  |
| Acquisition and Other Non-Recurring Costs | 326 |  | 518 |  |
| Non-Cash Purchase Accounting Adjustment | 20 |  | 80 |  |
| Adjusted EBITDA | $4113 | $5415 | $9561 | $10658 |

---

------

**Adjusted Earnings Per Share**

In evaluating our business, we consider and use adjusted EPS, a non-GAAP financial measure, as a supplemental measure of our business performance. We define adjusted EPS as net income attributable to Ultralife Corporation excluding the provision (benefit) for deferred income taxes divided by our weighted average shares outstanding on both a basic and diluted basis. We believe that this information is useful in providing period-to-period comparisons of our results by reflecting the portion of our tax provision that will be predominantly offset by our U.S. net operating loss carryforwards and other tax credits for the foreseeable future. We reconcile adjusted EPS to EPS, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EPS as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EPS to EPS and net income attributable to Ultralife Corporation.

---

| |
|:---|
| **ULTRALIFE CORPORATION AND SUBSIDIARIES** |
| **CALCULATION OF ADJUSTED EPS** |
| **(In Thousands Except Per Share Amounts)** |
| **(Unaudited)** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three-Month Period Ended** | **Three-Month Period Ended** | **Three-Month Period Ended** | **Three-Month Period Ended** | **Three-Month Period Ended** | **Three-Month Period Ended** |
|  | **June 30, 2025** | **June 30, 2025** | **June 30, 2025** | **June 30, 2024** | **June 30, 2024** | **June 30, 2024** |
|  | **Amount** | **Per** <br> **Basic** <br> **Share** | **Per** <br> **Diluted** <br> **Share** | **Amount** | **Per**<br> **Basic** <br> **Share** | **Per**<br> **Diluted**<br> **Share** |
| Net Income Attributable to Ultralife Corporation | $879 | $.05 | $.05 | $2969 | $.18 | $.18 |
| Deferred Tax Provision | 265 | .02 | .02 | 744 | .04 | .04 |
| Adjusted Net Income | $1144 | $.07 | $.07 | $3713 | $.22 | $.22 |
| Weighted Average Shares Outstanding |  | 16635 | 16656 |  | 16568 | 16825 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Six-Month Period Ended** | **Six-Month Period Ended** | **Six-Month Period Ended** | **Six-Month Period Ended** | **Six-Month Period Ended** | **Six-Month Period Ended** |
|  | **June 30, 2025** | **June 30, 2025** | **June 30, 2025** | **June 30, 2024** | **June 30, 2024** | **June 30, 2024** |
|  | **Amount** | **Per**<br> **Basic** <br> **Share** | **Per**<br> **Diluted** <br> **Share** | **Amount** | **Per** <br> **Basic**<br> **Share** | **Per** <br> **Diluted** <br> **Share** |
| Net Income Attributable to Ultralife Corporation | $2744 | $.17 | $.16 | $5860 | $.36 | $.35 |
| Deferred Tax Provision | 609 | .03 | .04 | 1394 | .08 | .09 |
| Adjusted Net Income | $3353 | $.20 | $.20 | $7254 | $.44 | $.44 |
| Weighted Average Shares Outstanding |  | 16634 | 16671 |  | 16482 | 16661 |

---

------

---

| |
|:---|
| **Company Contact:** |
| <u>Ultralife Corporation</u> |
| **Philip A. Fain** |
| **(315) 210-6110** |
| <u>pfain@ulbi.com</u> |
| **Investor Relations Contact:** |
| <u>Alliance Advisors IR</u> |
| **Jody Burfening/Alex Villalta** |
| **(212) 838-3777** |

---

<u>avillalta@allianceadvisors.com</u>